Biodesix (BDSX) Projected to Post Quarterly Earnings on Thursday

Biodesix (NASDAQ:BDSX) is anticipated to issue its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.05) per share and revenue of $26.25 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Biodesix Stock Down 1.6%

Shares of NASDAQ BDSX opened at $12.57 on Thursday. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. Biodesix has a 1 year low of $3.44 and a 1 year high of $20.40. The stock’s 50-day simple moving average is $8.72 and its 200-day simple moving average is $8.11. The firm has a market cap of $100.06 million, a price-to-earnings ratio of -2.26 and a beta of 0.67.

Insider Activity

In other Biodesix news, Director Jack W. Schuler acquired 82,465 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was acquired at an average price of $10.96 per share, with a total value of $903,816.40. Following the transaction, the director directly owned 1,463,210 shares in the company, valued at approximately $16,036,781.60. This represents a 5.97% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Scott Hutton sold 3,559 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total transaction of $35,874.72. Following the completion of the transaction, the chief executive officer directly owned 45,413 shares in the company, valued at $457,763.04. This represents a 7.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders bought 182,465 shares of company stock valued at $2,084,616 and sold 7,672 shares valued at $73,576. Insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BDSX. Trexquant Investment LP acquired a new stake in Biodesix in the fourth quarter worth $187,000. State Street Corp grew its position in shares of Biodesix by 15.6% during the fourth quarter. State Street Corp now owns 17,802 shares of the company’s stock worth $121,000 after acquiring an additional 2,400 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares during the period. Millennium Management LLC bought a new stake in Biodesix in the 3rd quarter valued at about $113,000. Finally, DRW Securities LLC acquired a new position in Biodesix during the 4th quarter valued at about $105,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price objective on shares of Biodesix in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Biodesix has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.